Neuland Laboratories Ltd

Neuland Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Neuland Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 23 February 2026, reflecting deteriorating fundamentals and increasingly negative technical indicators. The pharmaceutical company’s Mojo Score has dropped to 28.0, signalling heightened caution for investors amid a challenging financial and market environment.

Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a strong day change of 7.89%, the stock’s technical parameters, including MACD, RSI, and moving averages, suggest caution for investors amid mixed signals and deteriorating momentum.

Neuland Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s medium to long-term momentum amid challenging market conditions.

Neuland Laboratories Ltd recorded a robust intraday performance on 23 Feb 2026, surging to a day’s high of Rs 13,630, marking a 7.71% increase. This sharp uptick outpaced the broader Pharmaceuticals & Biotechnology sector and the Sensex, reflecting a notable rebound after three consecutive days of decline.

Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a sideways trend to a mildly bearish stance. This change has coincided with a significant downgrade in its Mojo Grade from Hold to Sell, reflecting growing concerns over the stock’s near-term performance despite its strong long-term returns.

Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a 2.85% gain on 18 Feb 2026, the stock’s overall outlook remains cautious with a recent downgrade to a Sell rating, underscoring the nuanced market sentiment in the Pharmaceuticals & Biotechnology sector.

Neuland Laboratories Ltd has seen its investment rating downgraded from Hold to Sell as of 14 February 2026, reflecting deteriorating financial trends and weakening technical indicators. Despite robust net sales growth over the past six months, the company’s profitability and operational efficiency have declined, prompting a reassessment of its valuation and outlook within the Pharmaceuticals & Biotechnology sector.

Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of early February 2026. Despite a recent downgrade in price performance, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential resilience in the near term.

Neuland Laboratories Ltd witnessed a sharp gap down at the opening of trade on 10 Feb 2026, reflecting heightened market concerns following recent developments. The stock opened with a loss of 6.75%, underperforming its sector and broader market indices, signalling a cautious sentiment among traders.

Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend, supported by recent price gains and evolving indicator signals. Despite mixed readings from key technical tools such as MACD, RSI, and moving averages, the stock’s recent performance suggests cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.

Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in bulk drugs and active pharmaceutical ingredients, reported a steep decline in profitability for Q3 FY26, with consolidated net profit plummeting 60.06% year-on-year to ₹40.57 crores despite revenue growth of 10.47%. The results, which saw the stock surge 6.53% to ₹13,886.95 following the announcement, reveal a company grappling with margin compression and operational challenges even as it maintains revenue momentum. With a market capitalisation of ₹16,998 crores, the small-cap pharmaceutical player faces critical questions about sustainability of its premium valuation amid deteriorating profitability metrics.

Neuland Laboratories Ltd recorded a robust intraday performance on 09 Feb 2026, surging to a day’s high of Rs 14,138.15, marking an 8.45% increase. This sharp rise outpaced the Pharmaceuticals & Biotechnology sector and the broader market, reflecting notable trading momentum and a positive reversal after two days of declines.

Neuland Laboratories Ltd has seen its investment rating downgraded from Hold to Sell as of 6 February 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, and subdued long-term financial growth despite recent quarterly improvements. The company’s stock performance continues to lag behind broader market indices, prompting a reassessment of its investment appeal.